WallStreetZenWallStreetZen

NASDAQ: LGND
Ligand Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Ligand Pharmaceuticals earnings were $197.2M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest LGND earnings report on Jun 30, 2026 announced Q2 2026 earnings of $48.5M, down 463.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, LGND reported annual earnings of $124.5M, with -3,186.6% growth. The next LGND earnings date is Nov 5, 2026.

LGND past earnings growth

How has LGND's earnings growth performed historically?

Company
N/A
Industry
18.27%
Market
91.49%
LGND's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
LGND's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance

LGND earnings history

Current Revenue
$290.5M
Current Earnings
$197.2M
Current Profit Margin
67.9%
LGND's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

LGND Return on Equity

Current Company
20.1%
Current Industry
-10.8%
Current Market
30.9%
LGND's Return on Equity (20.1%)... subscribe to Premium to read more.
High Return on Equity Performance

LGND Return on Assets

Current Company
11.7%
Current Industry
-10.7%
LGND is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when LGND announces earnings.

LGND Return on Capital Employed

Current Company
11.41%
Current Industry
-7.4%
LGND has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

LGND vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
LGND$278.98M$197.22M+28.45%$10.07
CGON-$221.36M-$224.38MN/A-$2.69
KOD-$216.41M-$241.99MN/A-$4.19
KNSA$119.96M$80.66M-87.84%$1.07
BLTE-$77.15M-$77.61MN/A-$2.31
View Top Biotech Stocks

LGND earnings dates

Next earnings date
Nov 5, 2026

Ligand Pharmaceuticals Earnings Reports & History FAQ

What were Ligand Pharmaceuticals's earnings last quarter?

On LGND's earnings call on Aug 6, 2026, Ligand Pharmaceuticals (NASDAQ: LGND) reported Q2 2026 earnings per share (EPS) of $2.42, up 868% year over year. Total LGND earnings for the quarter were $48.51 million. In the same quarter last year, Ligand Pharmaceuticals's earnings per share (EPS) was $0.25.

If you're new to stock investing, here's how to buy Ligand Pharmaceuticals stock.

When does Ligand Pharmaceuticals report earnings?

The next LGND earnings date is Nov 5, 2026. Add LGND to your watchlist to be reminded of Ligand Pharmaceuticals's next earnings date.

Is Ligand Pharmaceuticals profitable or losing money?

As of the last Ligand Pharmaceuticals earnings report, Ligand Pharmaceuticals is currently profitable. Ligand Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $197.22 million, a 359.97% decrease year over year.

What was LGND's earnings growth in the past year?

As of Ligand Pharmaceuticals's earnings date in Aug 6, 2026, Ligand Pharmaceuticals's earnings has grown year over year. LGND earnings in the past year totalled $197.22 million.

What are Ligand Pharmaceuticals's earnings expectations?

The current EPS estimate for Ligand Pharmaceuticals's earnings report in Nov 5, 2026 is $1.42.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.